CVI Holdings’s CorMedix CRMD Stock Holding History

CVI Holdings’s Portfolio CRMD Stock Details CRMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-28,500	Closed	-$269K	–	65
2019 Q1	$269K	Buy	+28,500	New	+$257K	0.25%	30

Other funds holding CRMD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Nomura Holdings Tokyo, Japan $37.7B AUM 34.44% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EIM

Elliott Investment Management West Palm Beach, Florida $20.1B AUM 60.76% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

CVI Holdings's CRMD Position: Q3 2023 in Review

CVI Holdings sold out of CorMedix (CRMD) in Q3 2023, closing a stake of 1,105,300 shares — an estimated $4.38M sold.

CVI Holdings first reported a position in CRMD in Q3 2019 and held it in 2 quarters. The position peaked at $4.38M in Q2 2023. 92 funds tracked by Wall St. Rank hold CRMD as of Q3 2023.

CVI Holdings reported no remaining CorMedix position as of Q3 2023 after selling out during the quarter.
CVI Holdings sold 1,105,300 CorMedix shares in Q3 2023, an estimated $4.38M.
CVI Holdings first reported a position in CorMedix in Q3 2019 and held it in 2 quarters.
CVI Holdings's CorMedix position peaked at $4.38M in Q2 2023.
92 funds tracked by Wall St. Rank held CorMedix as of Q3 2023.

Based on CVI Holdings's 13F filing for Q3 2023, filed 14 Nov 2023.